Prednisone withdrawal 14 days after liver transplantation with mycophenolate: a prospective trial of cyclosporine and tacrolimus

Transplantation
M D StegallI Kam

Abstract

The long-term complications of immunosuppressive therapy such as diabetes, hypercholesterolemia, and hypertension are a major source of morbidity in liver transplant recipients. In this prospective, randomized, open-label study we completely withdrew prednisone (PRED) 14 days after liver transplantation in an effort to decrease these metabolic complications. Patients were maintained on mycophenolate mofetil (MMF) in combination with either cyclosporine (CsA; Neoral formulation) or tacrolimus (TAC). Thus, we also were able to compare CsA to TAC in patients not receiving PRED with respect to efficacy, toxicity, and effect on posttransplant metabolic complications. A total of 71 patients were randomized to receive either TAC-MMF (n=35) or CsA-MMF (n=36) after liver transplantation and were analyzed for patient and graft survival. Fifty-eight patients continued the immunosuppressive protocol for at least 6 months after transplantation and were analyzed for the incidence of acute rejection and the prevalence of diabetes, hypertension, and hypercholesterolemia. The 6-month patient survival rates were 94.4% for CsA-MMF and 88.6% for TAC-MMF. Corresponding 6-month graft survival rates were 88.7% and 85.71% with no immunologic graft los...Continue Reading

References

Oct 27, 1994·The New England Journal of Medicine·UNKNOWN U.S. Multicenter FK506 Liver Study Group
Dec 27, 1995·Transplantation·S V McDiarmidR W Busuttil
Jan 1, 1997·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·M D StegallI Kam
Feb 1, 1997·Transplantation Proceedings·R W Busuttil, C D Holt
Feb 1, 1997·Transplantation Proceedings·A GavlikA G Tzakis

❮ Previous
Next ❯

Citations

Feb 4, 2005·Liver Transplantation : Official Publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society·Olivier BoillotGeorge-Phillipe Pageaux
Sep 9, 1999·Liver Transplantation and Surgery : Official Publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society·E TotsukaJ J Fung
Mar 26, 2004·Transplantation Proceedings·H Furukawa, S Todo
Aug 11, 2001·Transplantation Proceedings·A V Reisaeter, A Hartmann
Aug 11, 2001·Transplantation Proceedings·P Marchetti
Jul 6, 2000·Immunopharmacology·T S Mele, P F Halloran
Feb 19, 1999·Journal of the American College of Surgeons·L W Teperman
Mar 10, 2001·Clinics in Liver Disease·S J MunozC Manzarbeitia
Feb 28, 2008·Nature Clinical Practice. Gastroenterology & Hepatology·Gregory T Everson
Jun 26, 1999·Journal of Gastroenterology and Hepatology·K L CoxR O Castillo
Apr 17, 2001·Liver Transplantation : Official Publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society·J F TrotterI Kam
May 12, 2001·Liver Transplantation : Official Publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society·J F TrotterG Everson
Nov 2, 2001·Liver Transplantation : Official Publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society·G A Levy
Oct 7, 2006·Current Opinion in Gastroenterology·K A Brown, D K Moonka
Dec 29, 1998·Current Opinion in Nephrology and Hypertension·P A Keown
Aug 2, 2005·Journal of Pediatric Gastroenterology and Nutrition·Abdulrahman Al-HussainiAnil Dhawan
Jun 18, 2004·Transplantation·Ronald W Busuttil, John R Lake
Aug 23, 2002·Clinical Pharmacokinetics·Uwe ChristiansAlfonso Lampen
Jul 12, 2002·Drugs·Maria L Raimondo, Andrew K Burroughs
Nov 24, 2007·BioDrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy·G V MazariegosJ Reyes
Jul 5, 2001·BioDrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy·B Fellström
Feb 28, 2001·Paediatric Drugs·I D van Mourik, D A Kelly
Jun 30, 2005·American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions·Hallvard Holdaas
Feb 18, 2009·World Journal of Gastroenterology : WJG·Marco SpadaBruno Gridelli
Aug 2, 2012·World Journal of Gastroenterology : WJG·Eric R Kallwitz
May 17, 2014·World Journal of Gastroenterology : WJG·Mina ShakerNaim Alkhouri
Feb 5, 2010·Journal of Transplantation·Sandeep Mukherjee, Urmila Mukherjee
Oct 24, 2002·American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons·Leslie W Miller
Oct 26, 2001·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·R MooreH Valantine
Mar 6, 2013·HPB : the Official Journal of the International Hepato Pancreato Biliary Association·Shawn J PelletierJeffrey D Punch
May 26, 2005·Liver Transplantation : Official Publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society·Piero Marchetti
Jul 29, 2005·Pediatric Transplantation·Valérie A McLinDominique C Belli
Nov 24, 2004·Liver Transplantation : Official Publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society·Georges-Philippe PageauxUNKNOWN French CHI-F-01 Study Group

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cellular Immunometabolism

Immunometabolism involves not only the way metabolites are digested by the immune system, but the way in which they can alter the pathway of the immune system. These responses occur in day-to-day healthy cell functioning, but can result in diseases, such as autoimmune disorders. Discover the latest research on cellular immunometabolism here.